14
May

08:00 AM PST

Clinical Operations

Name: Clinical Operations & Clinical Trial Supply Chain Strategy Meeting West Coast 2026
Start: 2026-01-01T08:00
End: 2025-05-14T18:00
Location: Hard Rock Hotel San Diego

&

Clinical Trial Supply Chain

Strategy Meeting West Coast USA 2026

Jumpstart Clinical Operations on Patient Centricity, Innovation and Efficiency

Hard Rock Hotel San Diego

Fully Booked

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Clinical Operations Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered.rnrnProventa International’s Clinical Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Clinical Operations professionals from across the West Coast in San Diego, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the West Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at Clinical Operations Strategy Meetings.

Amy Woo

Senior Director, Clinical Operations Uniquity Bio

David Crean

Managing Partner & Partner Cardiff Advisory LLC & 1004 Venture Partners

Elie Arslan

Head, Quality, Principal Investigator and Program Management Cellics Therapeutics, Inc.

George Ng

Chief Executive Officer Processa Pharmaceuticals

George Ng is a seasoned executive and entrepreneur in the life sciences industry, currently serving as Chief Executive Officer and Board Director at Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) and as a partner at PENG Life Science Ventures (PENG LSV). Previously, he was President, COO, and Board Director at Calidi Biotherapeutics, Inc. (NYSE: CLDI), where he led the company’s successful public listing.
Mr. Ng co-founded Scilex Pharmaceuticals, Inc. (NASDAQ: SCLX), guiding it through product development, clinical trials, FDA approval, $140 million in financing, and its commercial launch and sale. His leadership career also includes senior executive roles at Sorrento Therapeutics, BioDelivery Sciences, Spectrum Pharmaceuticals, and Alpharma (now part of Pfizer), contributing to multiple successful drug product launches.
Before entering industry, Mr. Ng was a partner at two Am Law 200 firms, where he founded and led a national life sciences practice. He has served on the boards of several biotech companies and is a frequent speaker on legal, regulatory, and business topics.
Mr. Ng holds a Juris Doctor from the University of Notre Dame School of Law and a B.A.S. in Biochemistry and Economics from the University of California, Davis.

Gregory Opiteck

Vice President Head of Translational Sciences Allogene Therapeutics

An early adopter & advocate of precision medicine-driven clinical development, Greg has led mechanism‑based translational strategies that link drug design, human biology, and clinical data to inform decision-making in early development programs for over 25 years. He currently serves as Vice President, Head of Translational Medicine, at Janux Therapeutics here in San Diego, CA, where he oversees hypothesis‑driven translational and biomarker approaches supporting the clinical development of tumor‑activated T‑cell engager therapeutics. His work focuses on integrating pharmacology, immune activation, and on‑tumor biology to drive therapeutic activity & safety by explaining variance to treatment in indications such as metastatic castration‑resistant prostate cancer (mCRPC), including the lead JANX007 TCE program. 
Prior to joining Janux, Greg was Vice President and Head of Precision and Translational Medicine at Affini-T Therapeutics and previously held roles of increasing responsibility in early clinical development at Receptos, Merck, and Bristol Myers Squibb. Greg earned his PhD from the University of North Carolina, Chapel Hill, and his BSc from the University of Notre Dame.

Jacqui Blem

Vice President, Clinical Operations Wugen

Joseph Shan

Vice President, Clinical Operations Adcentrx Therapeutics

Joe Stalder

Executive Director Project Management Mirati Therapeutics

John Mattison

Former Operating Partner, Chief Medical Information Officer Arsenal Capital Partners

Matthew Spear

Chief Development Officer / Chief Medical Officer Denovo Biopharma

Dr. Spear has been working in oncology and gene therapy research and development for over 30 years. He received a B.A. degree from Johns Hopkins University and an M.D. degree from Stanford University. Post-graduate training was in the Massachusetts General Hospital / Harvard University program. He has served as an Associate Professor on the faculty of the USC Keck School of Medicine, and the UCSD Medical School / UCSD Cancer Center where he managed a clinical practice, drug discovery/gene therapy research, and clinical trial programs for cancer. Dr. Spear led multiple oncology clinical development programs at Pfizer. He subsequently served as Chief Medical Officer and Senior Vice-President at Nereus Pharmaceuticals, followed by Head of Oncology and Head of Biotherapeutics at Sunovion Pharmaceuticals, then as a Vice-President at Incyte and Sangamo Therapeutics, and Chief Medical Officer at Poseida Therapeutics developing multiple CAR-T cell and gene therapy products. He is currently Chief Development Officer / Chief Medical Officer at Denovo Biopharma. He has also served as a CIRM CAR-T cell principal investigator, NIH / NCI study section, CPRIT grant review panel, biotechnology and pharmaceutical advisory boards, IRB/SRC, and scientific journal editorial review committees related to cancer and gene therapy, as well as authoring numerous scientific papers and patent applications.
CAR-T cell, RMAT, Gene Therapy, Gene Editing, AAV, HSV, transposon, hemophilia, Oncology, Hematology, NHL, myeloma, AML, MDS, prostate cancer, lung cancer, breast cancer, pancreatic cancer, GBM, H&N cancer, sarcoma, ovarian cancer, Oncolytic, Epigenetic, Biomarkers, Companion Diagnostics. Small Molecules, California Institute for Regenerative Medicine (CIRM), Immunotherapy, Vaccine, Antibody, Phage Display, sickle-cell, thalassemia, MPS I&II, MEK, PARP, CDK, VEGFR, Angiogenesis, VDA, HDAC, Proteosome, PI3K, BRD, JAK, PIM, FGFR, WT1, lysine-specific demethylase, OTC

Mehran Moghaddam

CEO OROX Biosciences, Inc.

Kimberly Ma

Senior Vice President, Clinical Development & Operations Abdera Therapeutics

First name	Last name	Job title	Company name	Photo URL	Bio Position
Amy	Woo	Senior Director, Clinical Operations	Uniquity Bio	https://proventainternational.com/wp-content/uploads/2026/05/facilitator-Recovered.jpg
David	Crean	Managing Partner & Partner	Cardiff Advisory LLC & 1004 Venture Partners	https://proventainternational.com/wp-content/uploads/2025/10/David-H.-Crean.jpg	David H. Crean is a distinguished executive with over 30 years of experience across the life sciences and healthcare sectors with roles in strategic biopharma, private equity, venture capital, and investment banking. His career journey is a unique blend of scientific knowledge, business savvy, and financial leadership, which has earned him a reputation as a mentor, investor and dealmaker. Dr. Crean currently serves as the Founder and Managing Partner of Cardiff Advisory LLC, an M&A advisory firm, and is a Venture Partner at 1004 Venture Partners, a healthcare investment fund. He holds a Ph.D. in Biophysics and an M.S. in Oncology from the State University of New York Buffalo, as well as an MBA in Finance from Pepperdine University.
Elie	Arslan	Head, Quality, Principal Investigator and Program Management	Cellics Therapeutics, Inc.	https://proventainternational.com/wp-content/uploads/2025/10/Elie-Arslan.jpg	Compliance driven, highly successful Quality leader, with over 21 years of extensive experience in Quality in Biopharmaceuticals, Biologics, and Medical Devices. I am comprehensively knowledgeable and experienced in GxP (GMP, GLP and GCP), with an MBA and a Master of Science in Biotechnology from Johns Hopkins University. Elie oversees various Quality and Regulatory responsibilities and thrive in a fast-paced dynamic environment. Elie has 12 years of CMO experience, including experience in releasing drug substances, drug products, aseptic filling operations for clinical trials to commercial automated large-scale production, experience small molecules, large molecules, oncology and gene therapy. Elie successfully hosted FDA, CA FDB and QP inspections for PAI and routine Quality System inspections since 2015.
George	Ng	Chief Executive Officer	Processa Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2023/05/George-Ng.jpg	George Ng is a seasoned executive and entrepreneur in the life sciences industry, currently serving as Chief Executive Officer and Board Director at Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) and as a partner at PENG Life Science Ventures (PENG LSV). Previously, he was President, COO, and Board Director at Calidi Biotherapeutics, Inc. (NYSE: CLDI), where he led the company’s successful public listing. Mr. Ng co-founded Scilex Pharmaceuticals, Inc. (NASDAQ: SCLX), guiding it through product development, clinical trials, FDA approval, $140 million in financing, and its commercial launch and sale. His leadership career also includes senior executive roles at Sorrento Therapeutics, BioDelivery Sciences, Spectrum Pharmaceuticals, and Alpharma (now part of Pfizer), contributing to multiple successful drug product launches. Before entering industry, Mr. Ng was a partner at two Am Law 200 firms, where he founded and led a national life sciences practice. He has served on the boards of several biotech companies and is a frequent speaker on legal, regulatory, and business topics. Mr. Ng holds a Juris Doctor from the University of Notre Dame School of Law and a B.A.S. in Biochemistry and Economics from the University of California, Davis.
Gregory	Opiteck	Vice President Head of Translational Sciences	Allogene Therapeutics	https://proventainternational.com/wp-content/uploads/2023/05/Gregory-Opiteck.jpg	An early adopter & advocate of precision medicine-driven clinical development, Greg has led mechanism‑based translational strategies that link drug design, human biology, and clinical data to inform decision-making in early development programs for over 25 years. He currently serves as Vice President, Head of Translational Medicine, at Janux Therapeutics here in San Diego, CA, where he oversees hypothesis‑driven translational and biomarker approaches supporting the clinical development of tumor‑activated T‑cell engager therapeutics. His work focuses on integrating pharmacology, immune activation, and on‑tumor biology to drive therapeutic activity & safety by explaining variance to treatment in indications such as metastatic castration‑resistant prostate cancer (mCRPC), including the lead JANX007 TCE program. Prior to joining Janux, Greg was Vice President and Head of Precision and Translational Medicine at Affini-T Therapeutics and previously held roles of increasing responsibility in early clinical development at Receptos, Merck, and Bristol Myers Squibb. Greg earned his PhD from the University of North Carolina, Chapel Hill, and his BSc from the University of Notre Dame.
Jacqui	Blem	Vice President, Clinical Operations	Wugen	https://proventainternational.com/wp-content/uploads/2025/07/Jacqui-Blem.jpg
Joseph	Shan	Vice President, Clinical Operations	Adcentrx Therapeutics	https://proventainternational.com/wp-content/uploads/2024/02/Joseph-Shan.jpg	Joseph (Joe) Shan, M.P.H., VP, Clinical Operations at Adcentrx Therapeutics, has nearly 30 years of clinical experience in biopharma and medical device companies. Nearly 25 years were focused on clinical development of oncology therapeutics, including radiopharmaceuticals, small molecules, targeted therapy, immunotherapy and cellular therapy. Prior to Adcentrx, Joe held leadership roles in Clinical Development Operations at Mosaic ImmunoEngineering, MEI Pharma, Elevar Therapeutics, Kiadis Pharma (formerly CytoSen Therapeutics) and was VP, Clinical & Regulatory Affairs and a corporate officer of Peregrine Pharmaceuticals for nearly a decade. Mr. Shan received his M.P.H. from George Washington University and B.S. from UCLA
Joe	Stalder	Executive Director Project Management	Mirati Therapeutics	https://proventainternational.com/wp-content/uploads/2023/03/Joe-Stalder.jpg	Joe Stalder is an Executive Director of Project Management at Mirati Therapeutics in San Diego, CA, co-founder of Groundswell Pharma Consulting, and editor of the book “Project Management for Drug Developers”. Joe has over 10 years of project management experience in pharmaceutical development in large and small companies. His experience includes Project Management department head, PMO head, and Lead Project Manager on several early- and late-stage development assets in oncology, infectious disease, cardiology, metabolism, and pulmonology. Joe is also a regular speaker at biopharma PPM conferences and is involved in biopharma PPM community organizations including PIPMG and BiopharmaPM.
John	Mattison	Former Operating Partner, Chief Medical Information Officer	Arsenal Capital Partners	https://proventainternational.com/wp-content/uploads/2025/10/John-Mattison.jpg
Matthew	Spear	Chief Development Officer / Chief Medical Officer	Denovo Biopharma	https://proventainternational.com/wp-content/uploads/2023/01/Matthew-Spear.jpg	Dr. Spear has been working in oncology and gene therapy research and development for over 30 years. He received a B.A. degree from Johns Hopkins University and an M.D. degree from Stanford University. Post-graduate training was in the Massachusetts General Hospital / Harvard University program. He has served as an Associate Professor on the faculty of the USC Keck School of Medicine, and the UCSD Medical School / UCSD Cancer Center where he managed a clinical practice, drug discovery/gene therapy research, and clinical trial programs for cancer. Dr. Spear led multiple oncology clinical development programs at Pfizer. He subsequently served as Chief Medical Officer and Senior Vice-President at Nereus Pharmaceuticals, followed by Head of Oncology and Head of Biotherapeutics at Sunovion Pharmaceuticals, then as a Vice-President at Incyte and Sangamo Therapeutics, and Chief Medical Officer at Poseida Therapeutics developing multiple CAR-T cell and gene therapy products. He is currently Chief Development Officer / Chief Medical Officer at Denovo Biopharma. He has also served as a CIRM CAR-T cell principal investigator, NIH / NCI study section, CPRIT grant review panel, biotechnology and pharmaceutical advisory boards, IRB/SRC, and scientific journal editorial review committees related to cancer and gene therapy, as well as authoring numerous scientific papers and patent applications. CAR-T cell, RMAT, Gene Therapy, Gene Editing, AAV, HSV, transposon, hemophilia, Oncology, Hematology, NHL, myeloma, AML, MDS, prostate cancer, lung cancer, breast cancer, pancreatic cancer, GBM, H&N cancer, sarcoma, ovarian cancer, Oncolytic, Epigenetic, Biomarkers, Companion Diagnostics. Small Molecules, California Institute for Regenerative Medicine (CIRM), Immunotherapy, Vaccine, Antibody, Phage Display, sickle-cell, thalassemia, MPS I&II, MEK, PARP, CDK, VEGFR, Angiogenesis, VDA, HDAC, Proteosome, PI3K, BRD, JAK, PIM, FGFR, WT1, lysine-specific demethylase, OTC
Mehran	Moghaddam	CEO	OROX Biosciences, Inc.	https://proventainternational.com/wp-content/uploads/2025/06/Mehran-F.-Moghaddam.jpg	Dr. Mehran Moghaddam is the Founder and the Chief Executive Officer of OROX Biosciences, Inc., leading efforts to develop bifunctional small molecules for oncology and inflammatory diseases. With three decades of biopharmaceutical experience, he has guided research and development across multiple therapeutic areas, including oncology, fibrosis, cardiovascular, and CNS disorders. Mehran previously held key scientific and leadership roles at Celgene, DuPont, and Pfizer, contributing to the discovery and development of groundbreaking therapies such as Revlimid®, Pomalyst®, and Otezla®.
Kimberly	Ma	Senior Vice President, Clinical Development & Operations	Abdera Therapeutics	https://proventainternational.com/wp-content/uploads/2026/01/Kimberly-Ma.jpg

Amy Woo, David Crean, Elie Arslan, George Ng, Gregory Opiteck, Jacqui Blem, Joseph Shan, Joe Stalder, John Mattison, Matthew Spear, Mehran Moghaddam, Kimberly Ma

Our Past Facilitators

Anthony Maida

Chief Clinical Officer – Translational Medicine Oncotelic Therapeutics, Inc.

Dr. Maida is currently Chief Clinical Officer – Translational Medicine for Oncotelic, Inc. focused on the immunotherapy of cancer and infectious disease.  Formerly he was Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc., a cancer vaccine company focused on therapy of patients with glioblastoma multiforme and prostate cancer.  He is responsible for the oversight of the clinical and scientific operations of Oncotelic Therapeutics, Inc.  Dr. Maida was formerly Vice President of Clinical Research and General Manager, Oncology, World-wide for PharmaNet, Inc.  Prior to coming to Pharmanet Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street, in the clinical development of therapeutic products and product/company acquisitions. For 30 years, Dr. Maida has focused on the clinical development of immunotherapies to treat patients with cancer.  Dr. Maida’s skill set includes the execution and oversight of finance, operations, research, and commercial clinical and scientific development, regulatory and manufacturing for the development of various therapeutic modalities.  Dr. Maida has served in a number of executive roles, including, Chairman, CEO, COO, CSO, CFO and business development.  Dr. Maida serves or has served on the advisory board of EndPoint BioCapital, Sdn Bhd (Kuala Lumpur, Malaysia), and as an advisor, consultant and technical analyst for CMX Capital, LLC, Sagamore Bioventures, Roaring Fork Capital, Toucan Capital, North Sound Capital, The Bonnie J. Addario Lung Cancer Foundation and Pediatric BioScience, Inc.  Additionally, Dr. Maida has been retained by Abraxis BioScience, Inc., Northwest BioTherapeutics, Inc. and Takeda Chemical Industries, Ltd. (Osaka, Japan). Dr. Maida sat on multiple public company boards and advisory committees.  Dr. Maida holds a B.A. degree in Biology, a B.A. Degree in History, a MBA, a MA in toxicology and a Ph.D. in Immunology.  He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the Society of Neuro-Oncology (SNO), the International Society for Biological Therapy of Cancer (iSBTc) and the American Chemical Society.  Dr. Maida holds a number of patents and patent applications associated with various therapeutic modalities and approaches.

Christie Quarles

Clinical Analytics Product Marketing Manager Revvity Signals

David Crean

Managing Partner & Partner Cardiff Advisory LLC & 1004 Venture Partners

Elie Arslan

Head, Quality, Principal Investigator and Program Management Cellics Therapeutics, Inc.

George Ng

Chief Executive Officer Processa Pharmaceuticals

Glenn Guthrie

Senior Principal Clinical Solutions Strategy Revvity Signals

Jacqui Blem

Vice President, Clinical Operations Wugen

Janal Urich

Vice President, Clinical Operations Atara Biotherapeutics

John Mattison

Former Operating Partner, Chief Medical Information Officer Arsenal Capital Partners

Joseph Shan

Vice President, Clinical Operations Adcentrx Therapeutics

Peter Stiegler

Vice President, Clinical Operations Oncology HUYA Bioscience International

Sandy Wiley

Former Senior Director Nonclinical & Translational Sciences (Department Head) MEI Pharma

Shaun MacEachern

Executive Director, Clinical Supply Chain Kumquat Biosciences Inc.

Tara Lehner

Vice President, Clinical Operations INmune Bio Inc.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

Clinical Trials San Diego

Clinical Operations & Clinical Trial Supply Chain Strategy Meeting West Coast 2024

&

Strategy Meeting West Coast USA 2026

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Hard Rock Hotel San Diego

Fresh Clinical Operations Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Our Facilitators

Amy Woo

David Crean

Elie Arslan

George Ng

Gregory Opiteck

Jacqui Blem

Joseph Shan

Joe Stalder

John Mattison

Matthew Spear

Mehran Moghaddam

Kimberly Ma

Our Past Facilitators

Anthony Maida

Christie Quarles

David Crean

Elie Arslan

George Ng

Glenn Guthrie

Jacqui Blem

Janal Urich

John Mattison

Joseph Shan

Peter Stiegler

Sandy Wiley

Shaun MacEachern

Tara Lehner

Our Agenda

See Which Topics Are Up For Discussion

Breakfast & Registration

Opening Keynote Presentation

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Refreshment Break

Networking/1-1 Meetings

Roundtable ( Pharma/Biotech )

Roundtable Tracks

SPONSOR

SPONSOR

SPONSOR

SPONSOR

SPONSOR

Networking Lunch

Networking / 1-1 Meetings

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Panel Discussion

Drinks & Canapes Reception

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

Our Sponsor

Key Opinion Leader

Partnering Sponsor

Our Past Sponsors

Co-Host Sponsor

Partnering Sponsor

Key Opinion Leader

Hard Rock Hotel San Diego